A share price of Immunovant Inc [IMVT] is currently trading at $30.72, down -0.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMVT shares have lost -0.39% over the last week, with a monthly amount drifted -2.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, Immunovant Awarded U.S. Patent for IMVT-1402. In a post published today on Yahoo Finance, Composition of matter patent issued with coverage until June 2043.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on March 28, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $50. Previously, Goldman started tracking the stock with Buy rating on March 13, 2024, and set its price target to $50. On February 20, 2024, JP Morgan initiated with a Overweight rating and assigned a price target of $51 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $55 on February 15, 2024. Deutsche Bank initiated its recommendation with a Buy and recommended $50 as its price target on December 12, 2023. UBS upgraded its rating to Buy for this stock on October 13, 2023, and upped its price target to $55. In a note dated September 26, 2023, Raymond James upgraded an Outperform rating on this stock but restated the target price of $40.
Immunovant Inc experienced fluctuations in its stock price throughout the past year between $14.11 and $45.58. Currently, Wall Street analysts expect the stock to reach $27.5 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $30.72 at the most recent close of the market. An investor can expect a potential drop of -10.48% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.61 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.96 points at the first support level, and at 29.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.33, and for the 2nd resistance point, it is at 31.95.
Immunovant Inc [IMVT] reported earnings per share of -$0.36 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.07 and a surprise factor of 16.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.45 per share as compared to estimates of -$0.47 per share, a difference of $0.02 representing a surprise of 4.30%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunovant Inc [NASDAQ:IMVT] is 22.14. As well, the Quick Ratio is 22.14, while the Cash Ratio is 21.52.
Transactions by insiders
Recent insider trading involved Salzmann Peter, Chief Executive Officer, that happened on Apr 09 ’24 when 4807.0 shares were sold. Chief Financial Officer, Barnett Eva Renee completed a deal on Apr 09 ’24 to sell 3689.0 shares. Meanwhile, Chief Development Officer Butchko Julia G. sold 1053.0 shares on Apr 09 ’24.
